Sun Pharma to raise stake in US-based Pharmazz to 22.7%

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%

Sun Pharma gets FDA approval for new device to treat skin disease

Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results in Osteoarthritis and Cartilage

Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles

Shaik Barak Tulla joins Sun Pharma as Sr. VP

Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla

US court lifts launch restrictions on Sun Pharma's autoimmune drug

Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise

Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025

This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

Sun Pharma to acquire 100% stake in Antibe Therapeutics

Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation

Briefs: Sun Pharmaceutical Industries and Biocon Biologics

The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI